What is the fair value of Abbott Laboratories (NYSE-ABT) stock?

The current fair value estimate for Abbott Laboratories (NYSE-ABT) is $106.98. This implies an estimated upside of 5.3% versus the current market price.

Is Abbott Laboratories (NYSE-ABT) undervalued or overvalued?

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 5.3% versus the current market price.

What is the analyst price target for NYSE-ABT stock?

The available analyst price target for Abbott Laboratories (NYSE-ABT) is $120.26. The analyst target implies estimated upside of 18.4%.

How is the financial health of Abbott Laboratories?

The current financial health read for Abbott Laboratories (NYSE-ABT) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is Abbott Laboratories's next earnings date?

The next earnings date currently listed for Abbott Laboratories (NYSE-ABT) is October 21, 2026.

Does Abbott Laboratories (NYSE-ABT) pay dividends?

Based on the current data, dividend yield is 2.5%.

What is the P/E ratio for Abbott Laboratories (NYSE-ABT)?

The current P/E ratio listed for Abbott Laboratories (NYSE-ABT) is 32.8x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

What is the market capitalization of Abbott Laboratories?

The current market capitalization listed for Abbott Laboratories is 177.1 B.

What is the enterprise value of Abbott Laboratories?

The current enterprise value listed for Abbott Laboratories is 204.9 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Abbott Laboratories?

The ticker symbol for Abbott Laboratories is NYSE-ABT, and the stock is listed on NYSE.

Where is Abbott Laboratories (NYSE-ABT) listed?

Abbott Laboratories (NYSE-ABT) is listed on NYSE.

What is the debt-to-total-capital ratio for Abbott Laboratories?

The current debt-to-total-capital ratio listed for Abbott Laboratories is 15.5%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for Abbott Laboratories?

The free float listed for Abbott Laboratories is 99.4%. Free float helps investors understand how much of the share base is available for public trading.

Abbott Laboratories (ABT) Fair Value & Stock Analysis

Abbott Laboratories (ABT)

Abbott Laboratories is a common stock listing on the NYSE representing an ordinary equity interest in Abbott Laboratories, a global healthcare company founded in 1888 and based in Abbott Park, Illinois. Through its subsidiaries, the company develops, manufactures, and markets healthcare products worldwide across four operating segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its portfolio includes branded and generic pharmaceuticals, diagnostic systems and tests, infant formula and other nutrition products, cardiovascular and diabetes care devices, and neuromodulation products for chronic pain and movement disorders. Abbott also supplies laboratory, transfusion medicine, molecular diagnostics, point-of-care, and rapid testing solutions used in clinical and laboratory settings.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Analyst Target Rating	Overall Financial Health	Dividend Yield	Next Earnings Date	P/E Ratio	Price-to-Book Ratio	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Payout Ratio	Free Cash Flow / Net Income
NYSE-ABT	$106.98	5.3% Upside	Fair	$120.26	18.4% Upside	Undervalued	Good	2.5%	October 21, 2026	32.8x	3.5x	3.8x	177.1 B	204.9 B	15.5%	99.4%	4.5	78.5%	144.9%